This refresh
Data-driven refresh June 25, 2026. The Top Picks are the Bull Rankings quality-growth screen — strong, growing businesses with durable returns at a fair price (PEG / EV-EBIT vs sector, ROIC, free cash flow), ranked across a 5224-ticker universe covering every US-listed common stock on NYSE, NASDAQ, NYSE American, and NYSE Arca (2551 passed the market-cap / liquidity screen; financials route to a separate card). Fundamentals from Yahoo Finance quoteSummary reconciled with as-reported SEC EDGAR filings; narrative authored by Groq (with Gemini and data-driven fallbacks).
Top Picks — quality compounders at a fair price
1. INCY — Incyte Corporation · score 90.5
Biotechnology · price $107.53 · 1Y $110.26 · 5Y $161.43 · 10Y $239.47
FCF $1.4b C+ · Rev +21.2% A- · D/E 0.01 A · P/E 15.2x A- · PEG 0.36 A
Why now. Incyte Corporation's JAKAFI and ICLUSIG product lines are driving a 21.2% revenue growth rate, with a 15.2 P/E ratio and a 0.36 PEG ratio indicating the company's growth is reasonably valued. This growth, combined with a 26.7% profit margin, positions Incyte for sustained compounding. The crux of this thesis rests on the company's ability to maintain its revenue growth trajectory, driven by its portfolio of therapeutics for rare diseases.
Moat. Incyte's durable edge stems from its portfolio of therapeutics, including JAKAFI and ICLUSIG, which have demonstrated efficacy in treating rare diseases such as myelofibrosis and chronic myeloid leukemia. The company's 25.5% ROE is a result of its pricing power, driven by the high unmet medical need for its products and the limited competition in these disease areas. This pricing power, combined with the high barriers to entry in the biopharmaceutical industry, protects Incyte's market position.
Risk. A key risk to Incyte's growth trajectory is the potential for increased competition in the rare disease space, which could lead to decelerating revenue growth and contracting margins. Additionally, the company's 0.01 debt-to-equity ratio, while currently low, could increase if Incyte were to take on more debt to fund research and development or acquisitions. A concrete signal that would confirm the bear case would be a significant decline in JAKAFI sales due to the emergence of a competing therapy.
Horizon. 1-3 yr $110.26 (analyst consensus (n=23)) — fundamentals + valuation re-rating. 5 yr $161.43 at ~8% CAGR — compounding case rests on the competitive position widening. 10 yr $239.47 if current growth sustains into durable earnings power.
2. DOCS — Doximity, Inc. · score 90.4
Health Information Services · price $19.85 · 1Y $25.42 · 5Y $37.22 · 10Y $55.21
FCF $326m C · Rev +13.1% B+ · D/E 0.01 A · P/E 20.3x B+ · PEG 0.59 A-
Why now. The bull case for DOCS rests on its ability to compound growth through its Doximity platform, which offers a personalized newsfeed and workflow tools like Ask and Scribe, with a profit margin of 30.4%, revenue growth of 13.1%, and a PEG ratio of 0.59, indicating the company's growth is undervalued. This growth persistence hinges on the platform's ability to retain medical professionals and expand its offerings, making it a high-quality compounder. The crux of this thesis is the company's capacity to maintain its profit margin while expanding its user base and offerings.
Moat. Doximity's durable edge stems from its HIPAA-compliant AI assistant, Ask, and its network effect, where the value of the platform increases with each additional medical professional who joins, creating a cost advantage for the company. The 20.6% ROE can be attributed to the pricing power from category leadership in providing medical professionals with a personalized newsfeed and workflow tools, making it difficult for competitors to quickly replicate this advantage.
Risk. The bear case against DOCS centers around its high beta of 1.29, indicating volatility, and the potential for decelerating growth, which could lead to a re-rating of the stock. If the company fails to expand its user base or maintain its profit margins, the bull thesis could be broken, with a concrete signal being a decline in revenue growth below 10% or a contraction in profit margins. The debt-to-equity ratio of 0.01 is currently not a concern but needs to be monitored.
Horizon. 1-3 yr $25.42 (analyst consensus (n=19)) — fundamentals + valuation re-rating. 5 yr $37.22 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $55.21 if current growth sustains into durable earnings power.
3. INTU — Intuit Inc. · score 89.8
Software - Application · price $255.07 · 1Y $488.17 · 5Y $714.73 · 10Y $1,060
FCF $7.8b B+ · Rev +15.6% B+ · D/E 0.33 B · P/E 15.6x A- · PEG 0.68 A-
Why now. The bull case for INTU rests on its ability to compound growth through its Global Business Solutions segment, particularly via QuickBooks services, with a $7.8B free cash flow, 15.6% revenue growth, and a 0.68 PEG ratio. This growth is driven by the company's financial management, payments, and capital products, and is further supported by its 21.9% profit margin and 22.2% ROE. The crux of this thesis is that INTU can maintain its revenue growth trajectory, driven by its QuickBooks services and Mailchimp marketing automation, which would justify its current valuation and drive further upside.
Moat. INTU's durable edge stems from its category leadership in financial management and business services, particularly through QuickBooks, which provides a high switching cost for its customers. The company's 22.2% ROE is a result of its pricing power, driven by its market position and the value proposition of its products. Additionally, the company's Mailchimp acquisition has expanded its marketing automation capabilities, further solidifying its competitive position.
Risk. The bear case against INTU centers on its valuation, with a 15.6 P/E ratio and a $69.8B market cap, which may be elevated given the company's growth prospects. Furthermore, the company's 0.33 debt-to-equity ratio, while manageable, could become a concern if interest rates rise or the company's growth slows. A concrete signal that would confirm the bear case would be a significant deceleration in revenue growth, which would undermine the bull thesis and lead to a re-rating of the stock.
Horizon. 1-3 yr $488.17 (analyst consensus (n=32)) — fundamentals + valuation re-rating. 5 yr $714.73 at ~23% CAGR — compounding case rests on the competitive position widening. 10 yr $1,060 if current growth sustains into durable earnings power.
4. ADBE — Adobe Inc. · score 89.7
Software - Application · price $193.41 · 1Y $282.27 · 5Y $413.27 · 10Y $613.06
FCF $10.3b A- · Rev +10.5% B · D/E 0.61 C+ · P/E 11.1x A · PEG 0.54 A-
Why now. The bull case for ADBE rests on its ability to compound growth through its Digital Media segment, which serves a wide range of customers from photographers to knowledge workers, with a 10.5% revenue growth rate and a $10.3B free cash flow, all while maintaining a 28.7% profit margin. This growth is further supported by a 0.54 PEG ratio, indicating the stock is reasonably valued given its growth prospects. The crux of this thesis is that ADBE can continue to leverage its customer base and product offerings to drive sustained growth.
Moat. ADBE's durable edge comes from its integrated platform and products in the Digital Experience segment, which enables brands and businesses to manage customer experiences, providing a high switching cost for its clients. The 62.8% ROE is a testament to the pricing power ADBE has due to its category leadership in digital media and experience creation, making it difficult for competitors to quickly replicate its business model.
Risk. The bear case against ADBE is centered around its high debt-to-equity ratio of 0.61 and a beta of 1.4, indicating a higher volatility compared to the market. If ADBE fails to manage its debt effectively or experiences a significant downturn in its end markets, it could lead to a contraction in its profit margin, currently at 28.7%, and confirm the bear case, breaking the bull thesis.
Horizon. 1-3 yr $282.27 (analyst consensus (n=32)) — fundamentals + valuation re-rating. 5 yr $413.27 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $613.06 if current growth sustains into durable earnings power.
5. LRN — Stride, Inc. · score 89.3
Education & Training Services · price $86.11 · 1Y $99.03 · 5Y $144.98 · 10Y $215.07
FCF $414m C · Rev +17.9% B+ · D/E 0.33 A- · P/E 13.5x A- · PEG 0.48 A
Why now. The bull case for LRN rests on its ability to compound growth through its proprietary online curriculum and software systems, with a 17.9% revenue growth rate and a 13.5 P/E ratio, which is supported by its $414m in free cash flow, making it an attractive growth investment. The company's technology-based products and services enable clients to support individualized learning for students, driving demand for its services. The crux of this thesis is that LRN can maintain its growth trajectory, driven by its integrated package of systems, services, and products, which will persist due to its strong position in the education market.
Moat. LRN's durable edge is its ability to provide a comprehensive and integrated package of online curriculum, software systems, and educational services, which creates a high switching cost for its clients. The company's 18.8% ROE is a result of its pricing power, driven by its category leadership in the virtual and blended public school market. This advantage is difficult for competitors to replicate, as it requires significant investment in technology and educational expertise, making it a sustainable moat for LRN.
Risk. The bear case for LRN is that its growth may decelerate due to increased competition in the online education market, which could lead to a contraction in its 12.2% profit margin. Additionally, the company's 0.33 debt-to-equity ratio, although relatively low, may increase if it pursues aggressive expansion plans, which could put pressure on its balance sheet. A concrete signal that would confirm the bear case is a decline in its revenue growth rate, which would break the bull thesis and indicate that LRN is losing its competitive edge.
Horizon. 1-3 yr $99.03 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $144.98 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $215.07 if current growth sustains into durable earnings power.
6. PCTY — Paylocity Holding Corporation · score 89.1
Software - Application · price $100.48 · 1Y $154.16 · 5Y $225.70 · 10Y $334.81
FCF $487m C · Rev +14.8% B+ · D/E 0.11 B+ · P/E 21.5x B+ · PEG 0.82 B+
Why now. The bull case for PCTY rests on its ability to compound growth through its cloud-based human capital management and payroll software solutions, with a 14.8% revenue growth rate and a 21.5 P/E ratio that is justified by its 16.1% profit margin. This growth is driven by its comprehensive suite of products, including payroll, HR, and talent solutions, which position it for long-term success. The crux of this thesis is that PCTY can maintain its 0.82 PEG ratio, indicating that its growth is undervalued relative to its current price.
Moat. PCTY's durable edge is its ability to provide a unified platform for human capital management, time and attendance, and payroll solutions, which creates switching costs for its customers and makes it difficult for competitors to replicate its offerings. Its 21.9% ROE is a result of its pricing power, driven by its category leadership in cloud-based HCM and payroll software. This moat is further reinforced by its low 0.11 debt-to-equity ratio, which provides financial flexibility to invest in its business.
Risk. The bear case for PCTY is that its 0.51 beta indicates a relatively low volatility, but its $5.4b market cap and 100.48 current price may be vulnerable to a downturn in the software industry. Additionally, the company's 3.4 PS ratio is relatively high, which could be a concern if revenue growth slows down. A concrete signal that would confirm the bear case is if PCTY's revenue growth rate were to decline significantly, breaking the bull thesis.
Horizon. 1-3 yr $154.16 (analyst consensus (n=19)) — fundamentals + valuation re-rating. 5 yr $225.70 at ~18% CAGR — compounding case rests on the competitive position widening. 10 yr $334.81 if current growth sustains into durable earnings power.
7. ADMA — ADMA Biologics, Inc. · score 88.9
Biotechnology · price $8.72 · 1Y $17.60 · 5Y $25.77 · 10Y $38.23
1Y -53% D · Rev +19.6% B+ · ROE 42.4% A · FCF $108m C
Why now. ADMA Biologics is a compelling growth story, driven by its specialty plasma-derived biologics for immune deficiencies and infectious diseases, with 19.6% revenue growth and a 32.4% profit margin, supported by a $108m free cash flow, positioning it for sustained compounding. The company's ability to maintain high margins while growing revenue rests on its pricing power in niche markets like primary humoral immunodeficiency treatment with products such as BIVIGAM and ASCENIV. The crux of this thesis is the persistence of this high-margin growth, underpinned by the demand for its specific biologics.
Moat. ADMA's durable edge stems from its proprietary products like Nabi-HB for Hepatitis B treatment and its network of Plasma Collection Centers, which provide a steady supply of raw materials for its biologics. The 42.4% ROE is a testament to the pricing power derived from its category leadership in specific immune deficiency treatments, a position that is hard for competitors to replicate quickly due to regulatory and operational barriers. This advantage is further reinforced by the high switching costs for patients and healthcare providers, ensuring loyalty to ADMA's products.
Risk. The strongest argument against ADMA is the risk of increased competition from larger biopharmaceutical companies entering the plasma-derived biologics market, potentially pressuring margins. With a debt-to-equity ratio of 1.11, ADMA's financial flexibility to respond to such competitive pressures is somewhat constrained. A concrete signal that would confirm the bear case is a significant decline in ADMA's profit margin, indicating an inability to maintain pricing power in the face of increased competition.
Horizon. 1-3 yr $17.60 (analyst consensus (n=5)) — fundamentals + valuation re-rating. 5 yr $25.77 at ~24% CAGR — compounding case rests on the competitive position widening. 10 yr $38.23 if current growth sustains into durable earnings power.
8. HRMY — Harmony Biosciences Holdings, Inc. · score 87.9
Biotechnology · price $34.13 · 1Y $44.36 · 5Y $64.95 · 10Y $96.35
1Y +8% C+ · Rev +21.5% A- · ROE 16.0% B+ · FCF $342m C
Why now. The bull case for HRMY rests on its ability to compound growth through its novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy, driven by WAKIX (pitolisant), with a 21.5% revenue growth rate and a 16.2% profit margin, all while maintaining a 0.18 debt-to-equity ratio, which suggests a strong financial foundation for sustained growth, and the crux is whether the company can continue to expand its product offerings and indications, such as the treatment of Prader-Willi Syndrome (PWS) and Myotonic Dystrophy (DM1), to drive long-term value creation.
Moat. HRMY's durable edge is rooted in its proprietary molecule, pitolisant, which has a novel mechanism of action, providing a competitive advantage in the treatment of rare neurological diseases, and its 16% ROE suggests pricing power from category leadership in this space, which is further reinforced by its ability to develop and commercialize therapies for patients with rare neurological diseases, making it difficult for competitors to quickly replicate its success.
Risk. The bear case against HRMY centers on the potential risks associated with its concentration in a limited number of products and indications, particularly WAKIX (pitolisant), and the 0.97 beta suggests that the stock may be sensitive to market volatility, and if the company fails to expand its product pipeline or experiences setbacks in its clinical trials, such as the Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS), it could lead to a decline in its stock price, with a concrete signal being a failure to meet analyst expectations or a significant delay in its clinical trials.
Horizon. 1-3 yr $44.36 (analyst consensus (n=11)) — fundamentals + valuation re-rating. 5 yr $64.95 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $96.35 if current growth sustains into durable earnings power.
9. NUTX — Nutex Health Inc. · score 87.3
Medical Care Facilities · price $149.10 · 1Y $235.50 · 5Y $344.80 · 10Y $511.48
1Y +25% B+ · Rev +82.4% A · ROE 27.8% A- · FCF $269m C
Why now. NUTX is a compelling growth opportunity due to its impressive 82.4% revenue growth rate, driven by its Hospital segment, which offers a range of healthcare services including emergency room care, inpatient care, and behavioural health, with a 10.9 P/E ratio and $269m in free cash flow, the company is well-positioned for continued expansion, and the crux of this thesis rests on the ability to maintain this growth trajectory.
Moat. NUTX's durable edge stems from its Population Health Management segment, which provides management, administrative, and other support services to its affiliated hospitals and physician groups, generating a 27.8% ROE, driven by pricing power from category leadership in healthcare services, and a cost advantage from its network of micro hospitals, specialty hospitals, and hospital outpatient departments, making it difficult for competitors to replicate quickly.
Risk. The primary threat to NUTX is its high 2.06 beta, indicating significant volatility, and a 0.79 debt-to-equity ratio, which may become a concern if interest rates rise, furthermore, the company's $1.0b market cap and 10.9 P/E ratio may be elevated, and a concrete signal that would confirm the bear case is a decline in revenue growth rate or a decrease in profit margin, which would break the bull thesis.
Horizon. 1-3 yr $235.50 (analyst consensus (n=4)) — fundamentals + valuation re-rating. 5 yr $344.80 at ~18% CAGR — compounding case rests on the competitive position widening. 10 yr $511.48 if current growth sustains into durable earnings power.
10. NVDA — NVIDIA Corporation · score 86.5
Semiconductors · price $195.74 · 1Y $298.93 · 5Y $437.67 · 10Y $649.25
FCF $119.1b A · Rev +65.5% A · D/E 0.07 A- · P/E 30.0x B · PEG 0.61 A-
Why now. The bull case for NVDA rests on its dominant position in the data center scale AI infrastructure market, driven by its Compute & Networking segment, which has delivered 65.5% revenue growth FY YoY, with a 63% profit margin and $119.1b in free cash flow TTM, all of which underpin a 30 P/E ratio that, given the 0.61 PEG ratio, suggests the growth is not only strong but also reasonably priced.
Moat. NVIDIA's durable edge stems from its leadership in providing data center accelerated computing and networking platforms, as well as artificial intelligence solutions, which are critical for its customers' operations, thereby creating significant switching costs and network effects, particularly evident in its 81.7% ROE, which is a result of its pricing power from category leadership in the AI infrastructure market.
Risk. The bear case against NVDA centers on its high valuation, with a $4.7T market cap and a 30 P/E ratio, which may be unsustainable if growth decelerates, and its high beta of 2.2, indicating volatility, meaning if the company fails to meet its high growth expectations, the stock could correct sharply, with a key signal being a significant drop in its 65.5% revenue growth rate.
Horizon. 1-3 yr $298.93 (analyst consensus (n=59)) — fundamentals + valuation re-rating. 5 yr $437.67 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $649.25 if current growth sustains into durable earnings power.
11. EXLS — ExlService Holdings, Inc. · score 86.1
Information Technology Services · price $25.22 · 1Y $41.75 · 5Y $61.13 · 10Y $90.68
FCF $297m C · Rev +13.6% B+ · D/E 0.67 C+ · P/E 16.1x A- · PEG 0.84 B+
Why now. The bull case for EXLS rests on its ability to compound growth through its digital operations and solutions, particularly in the Insurance and Healthcare segments, where it provides claims management, premium and benefit administration, and actuarial and risk analytics, with a 13.6% revenue growth rate, a 16.1 P/E ratio, and a 0.84 PEG ratio, all of which suggest a strong and sustainable growth trajectory, hinging on the company's ability to maintain its 11.7% profit margin.
Moat. EXLS's durable edge stems from its expertise in analytics-driven services, such as policy research, digital marketing, and underwriting support, which creates a high switching cost for its clients, as well as its 32.3% ROE, driven by pricing power from its category leadership in the Insurance and Healthcare segments, making it difficult for competitors to replicate its business model quickly.
Risk. The bear case against EXLS centers on its debt-to-equity ratio of 0.67, which, although not alarmingly high, indicates a level of financial leverage that could become problematic if interest rates rise or the company's cash flow generation falters, potentially confirming the bear case if the company's 25.14 week 52 low becomes a new resistance level.
Horizon. 1-3 yr $41.75 (analyst consensus (n=8)) — fundamentals + valuation re-rating. 5 yr $61.13 at ~19% CAGR — compounding case rests on the competitive position widening. 10 yr $90.68 if current growth sustains into durable earnings power.
12. FISV — Fiserv, Inc. · score 85.3
Sector n/a · price $47.53 · 1Y $70.00 · 5Y $102.49 · 10Y $152.03
FCF $4.1b B · Rev +9.3% B · D/E n/a · P/E 8.1x A- · PEG n/a
Why now. Fiserv's high-quality compounder status is driven by its 9.3% revenue growth, $4.1b free cash flow, and 19.7% profit margin, making it an attractive growth investment. The company's ability to generate significant free cash flow and maintain a high profit margin is crucial for its long-term success. The crux of this thesis rests on Fiserv's ability to sustain its revenue growth and maintain its high profit margin.
Moat. Fiserv's durable edge is its ability to generate a 12.2% return on equity, driven by its pricing power and high profit margins. This is attributed to its strong position in the growth segment, where it can maintain high margins due to its market leadership. A competitor would struggle to replicate this advantage quickly due to the high barriers to entry in this segment.
Risk. The strongest argument against Fiserv is its 52-week low of $47.04, which is close to its current price, indicating a potential lack of momentum. Additionally, the analyst recommendation of 'hold' suggests that the market is not overly optimistic about the company's prospects. If Fiserv fails to deliver on its revenue growth expectations, it could confirm the bear case and break the bull thesis.
Horizon. 1-3 yr $70.00 (analyst consensus (n=26)) — fundamentals + valuation re-rating. 5 yr $102.49 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $152.03 if current growth sustains into durable earnings power.
13. CARG — CarGurus, Inc. · score 84.8
Auto & Truck Dealerships · price $31.03 · 1Y $37.38 · 5Y $54.73 · 10Y $81.20
FCF $293m C · Rev +13.7% B+ · D/E 0.79 B · P/E 16.3x B+ · PEG 0.95 B+
Why now. The bull case for CarGurus, Inc. rests on its ability to compound growth through its online automotive marketplace, specifically the Digital Deal and Dealership Mode products, which are driving a 13.7% revenue growth rate, a 15.9% profit margin, and a 62.9% return on equity. This growth is further supported by the company's strong free cash flow of $293m, which will likely persist given the company's durable competitive advantage. The crux of this thesis is that CarGurus can maintain its growth trajectory, driven by its innovative products and extensive network of dealers.
Moat. CarGurus' durable edge stems from its integrated suite of products, including its online automotive marketplace, which connects a large audience of car shoppers with an extensive network of dealers. This network effect, combined with the company's 62.9% return on equity, driven by pricing power from category leadership in the online automotive marketplace, makes it difficult for competitors to replicate quickly. Additionally, the company's partnerships with financing services companies and auto manufacturers provide a cost advantage, further solidifying its competitive position.
Risk. The bear case against CarGurus, Inc. centers on the company's elevated 16.3 price-to-earnings ratio and 1.21 beta, which may indicate that the stock is overvalued and volatile. Furthermore, the company's 0.79 debt-to-equity ratio and 13.7% revenue growth rate, although strong, may not be sustainable in the long term. A concrete signal that would confirm the bear case is a decline in revenue growth rate or a decrease in profit margin, which would break the bull thesis and indicate that the company's growth trajectory is not as persistent as expected.
Horizon. 1-3 yr $37.38 (analyst consensus (n=13)) — fundamentals + valuation re-rating. 5 yr $54.73 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $81.20 if current growth sustains into durable earnings power.
14. IT — Gartner, Inc. · score 84.4
Information Technology Services · price $126.63 · 1Y $165.00 · 5Y $241.58 · 10Y $358.36
FCF $1.3b C+ · Rev +3.7% C+ · D/E n/a · P/E 12.5x A- · PEG 0.53 A-
Why now. The bull case for Gartner, Inc. rests on its ability to compound growth through its Insights segment, which delivers high-margin, subscription-based research and advisory services, with a PEG ratio of 0.53 indicating undervaluation given its revenue growth of 3.7% and a profit margin of 11.4%. This growth, combined with a free cash flow of $1.3B, positions the company for sustained expansion. The crux of this thesis is the persistence of this growth, driven by the stickiness of its subscription model and the essential nature of its insights for business decision-making.
Moat. Gartner's durable edge stems from its network of business and technology experts, providing direct access to clients through its subscription services, creating a switching cost that protects its client base. This expertise, combined with its extensive published content, data, and benchmarks, makes it difficult for competitors to replicate its offerings quickly, thereby maintaining its competitive advantage.
Risk. The bear case against Gartner, Inc. is rooted in its dependence on the Conferences segment, which, despite offering valuable networking opportunities, may face cyclicality in demand due to economic downturns or shifts in executive priorities. With a beta of 0.93, the company's stock price may be sensitive to broader market fluctuations, and any significant decline in conference attendance or a failure to adapt its Insights segment to evolving client needs could confirm the bear case and undermine the bull thesis.
Horizon. 1-3 yr $165.00 (analyst consensus (n=13)) — fundamentals + valuation re-rating. 5 yr $241.58 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $358.36 if current growth sustains into durable earnings power.
15. EPAM — EPAM Systems, Inc. · score 83.8
Information Technology Services · price $77.37 · 1Y $144.06 · 5Y $210.91 · 10Y $312.87
FCF $544m C+ · Rev +15.4% B+ · D/E 0.08 B+ · P/E 11.1x A · PEG 0.40 A
Why now. The bull case for EPAM Systems, Inc. rests on its ability to compound growth through its digital platform engineering and software development services, with a 15.4% revenue growth rate and a 11.1 P/E ratio, all while maintaining a 7% profit margin. This growth is driven by its engineering services, including requirements analysis and platform selection, customization, cross-platform migration, implementation, and integration. The crux of this thesis is that EPAM can sustain this growth rate, driven by its cloud services and data, analytics, and artificial intelligence offerings.
Moat. EPAM's durable edge comes from its integrated engineering practices and smart automation services, which create switching costs for its clients. The company's 11.3% ROE is a result of its pricing power, driven by its category leadership in digital platform engineering and software development. This advantage is difficult for competitors to replicate quickly, as it requires significant investment in talent, technology, and process development.
Risk. The bear case against EPAM is that its 1.4 beta and 0.08 debt-to-equity ratio may indicate a higher risk profile, particularly if the company's growth rate decelerates. If EPAM's revenue growth rate were to slow significantly, its valuation multiple could contract, leading to a decline in the stock price. A concrete signal that would confirm the bear case is a decline in EPAM's revenue growth rate below 10%.
Horizon. 1-3 yr $144.06 (analyst consensus (n=18)) — fundamentals + valuation re-rating. 5 yr $210.91 at ~22% CAGR — compounding case rests on the competitive position widening. 10 yr $312.87 if current growth sustains into durable earnings power.
16. DXCM — DexCom, Inc. · score 83.5
Medical Devices · price $68.65 · 1Y $85.24 · 5Y $124.80 · 10Y $185.13
1Y -18% D · Rev +15.6% B+ · ROE 31.5% A · FCF $1.4b C+
Why now. The bull case for DXCM rests on its ability to compound growth through its continuous glucose monitoring (CGM) systems, specifically the Dexcom G7 and G7 15 Day, with a 15.6% revenue growth rate and a 19.3% profit margin, driven by its $1.4B in free cash flow, which persists due to its strong product lineup and increasing demand for diabetes management solutions.
Moat. DXCM's durable edge stems from its integrated CGM systems like the Dexcom G7, which offers a unique value proposition to diabetics, supported by its 31.5% return on equity, driven by pricing power from category leadership in the CGM market, making it difficult for competitors to quickly replicate its offerings.
Risk. The bear case against DXCM is centered around its elevated 29.5 P/E ratio and 1.44 beta, which may indicate overvaluation, and the risk that competitors could develop similar CGM systems, potentially disrupting DXCM's growth trajectory, with a concrete signal being a decline in its 15.6% revenue growth rate.
Horizon. 1-3 yr $85.24 (analyst consensus (n=25)) — fundamentals + valuation re-rating. 5 yr $124.80 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $185.13 if current growth sustains into durable earnings power.
17. VEEV — Veeva Systems Inc. · score 83.5
Health Information Services · price $158.08 · 1Y $244.59 · 5Y $358.11 · 10Y $531.23
FCF $1.7b C+ · Rev +16.3% B+ · D/E 0.01 A- · P/E 28.0x B · PEG 0.73 A-
Why now. Veeva Systems Inc. is a compelling growth investment due to its robust revenue growth of 16.3% and high profit margin of 28.4%, driven by its Veeva Commercial Cloud and Veeva Data Cloud offerings, which together contribute to a PEG ratio of 0.73, indicating undervaluation. The company's strong financial position, with a debt-to-equity ratio of 0.01, further supports its growth potential. The bull case rests on the persistence of this growth, driven by the expanding adoption of cloud-based software in the life sciences industry.
Moat. Veeva's durable competitive advantage stems from its comprehensive suite of cloud-based software solutions, including Veeva Vault CRM Suite and Veeva OpenData, which provide a high degree of customer stickiness due to the significant switching costs and data integration complexities. The company's ROE of 12.9% is a testament to its pricing power, driven by its category leadership in the life sciences industry, making it difficult for competitors to replicate its business model.
Risk. The primary risk to the Veeva investment thesis is the potential for decelerating revenue growth, driven by increasing competition from other cloud-based software providers, which could lead to a contraction in the company's profit margin of 28.4%. A significant increase in the debt-to-equity ratio of 0.01 could also undermine the company's financial flexibility and exacerbate the impact of any growth slowdown. The bear case would be confirmed if Veeva's revenue growth falls below 10% and its profit margin contracts by more than 5%.
Horizon. 1-3 yr $244.59 (analyst consensus (n=27)) — fundamentals + valuation re-rating. 5 yr $358.11 at ~18% CAGR — compounding case rests on the competitive position widening. 10 yr $531.23 if current growth sustains into durable earnings power.
18. YELP — Yelp Inc. · score 82.4
Internet Content & Information · price $22.92 · 1Y $26.50 · 5Y $38.80 · 10Y $57.56
FCF $281m C · Rev +3.7% C+ · D/E 0.25 A- · P/E 10.5x A- · PEG 0.57 A-
Why now. The bull case for YELP rests on its ability to compound growth through its cost-per-click advertising and multi-location Ad products, with a 10.5 P/E ratio, 0.57 PEG ratio, and $281m in free cash flow, indicating a strong and undervalued franchise. The crux of this thesis is that YELP's 3.7% revenue growth rate will persist, driven by its diverse platform covering various categories, including restaurants, shopping, and health. The key to this persistence is YELP's 9.5% profit margin, which suggests efficient operations and the potential for further expansion.
Moat. YELP's durable edge is its network effect, driven by its large user base and diverse platform, which creates a self-reinforcing cycle of more businesses listing on the platform, attracting more users, and in turn, more businesses. This is evident in its 22% ROE, which can be attributed to its pricing power from category leadership in local business listings. A competitor would struggle to replicate this network effect quickly, as it requires a significant investment of time and resources to build a similar user base and business listings.
Risk. The bear case against YELP is that its growth may decelerate due to increasing competition from other review platforms, which could lead to a contraction in its 0.9 price-to-sales ratio and a decrease in its $26.50 analyst consensus 1-yr target. The concrete signal that would confirm this bear case is a decline in YELP's 3.7% revenue growth rate, indicating that the company is struggling to maintain its market share. Additionally, YELP's 0.25 debt-to-equity ratio, while relatively low, could become a concern if the company takes on more debt to finance its operations or acquisitions.
Horizon. 1-3 yr $26.50 (analyst consensus (n=8)) — fundamentals + valuation re-rating. 5 yr $38.80 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $57.56 if current growth sustains into durable earnings power.
19. META — Meta Platforms, Inc. · score 82.3
Internet Content & Information · price $542.87 · 1Y $827.32 · 5Y $1,211 · 10Y $1,797
FCF $48.3b A · Rev +22.2% A- · D/E 0.36 B+ · P/E 19.7x B · PEG 0.81 B+
Why now. The bull case for META rests on its ability to compound growth through its Family of Apps (FoA) segment, which includes Facebook, Instagram, and Messenger, with a revenue growth rate of 22.2% and a profit margin of 32.8%, driven by its strong positioning in the internet content and information sector, and further supported by its PEG ratio of 0.81, indicating undervaluation given its growth prospects.
Moat. META's durable edge is rooted in its network effects across its FoA segment, where the value of each platform increases with the number of users, creating a self-reinforcing cycle that competitors struggle to replicate, as evidenced by its ROE of 29%, which is a result of its pricing power from category leadership in social media and online advertising.
Risk. The bear case against META centers on its high debt-to-equity ratio of 0.36 and its beta of 1.23, indicating a higher volatility compared to the market, and the risk that its Reality Labs (RL) segment may not achieve expected returns, potentially leading to a contraction in its profit margin of 32.8% and impacting its ability to maintain its current growth trajectory.
Horizon. 1-3 yr $827.32 (analyst consensus (n=59)) — fundamentals + valuation re-rating. 5 yr $1,211 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $1,797 if current growth sustains into durable earnings power.
20. RMD — ResMed Inc. · score 82.3
Medical Instruments & Supplies · price $198.60 · 1Y $260.60 · 5Y $381.54 · 10Y $566.00
1Y -23% D · Rev +9.8% B · ROE 23.4% A- · FCF $1.8b C+
Why now. ResMed's Sleep and Breathing Health segment, driven by products like ApneaLink Air and NightOwl, is poised to compound growth due to its 27.4% profit margin, 9.8% revenue growth, and 19.1 P/E ratio, which collectively underpin the bull case for owning RMD, resting on the crux of sustained 23.4% ROE.
Moat. ResMed's durable edge stems from its category leadership in sleep apnea diagnosis and treatment, exemplified by pricing power from products like ApneaLink Air, which is difficult for competitors to replicate quickly, thereby maintaining a high 23.4% ROE through mechanisms like pricing power and cost advantages in manufacturing and distribution.
Risk. The bear case against RMD is led by the threat of increased competition in the sleep apnea market, potentially contracting ResMed's 27.4% profit margin, coupled with a 0.78 beta that indicates sensitivity to market volatility, and a 1.16 PEG ratio that may suggest the stock is fairly valued, with the concrete signal of declining revenue growth confirming the bear case.
Horizon. 1-3 yr $260.60 (analyst consensus (n=15)) — fundamentals + valuation re-rating. 5 yr $381.54 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $566.00 if current growth sustains into durable earnings power.
21. CVSA — Covista Inc. · score 81.9
Education & Training Services · price $124.16 · 1Y $156.25 · 5Y $228.77 · 10Y $339.36
FCF $336m C · Rev +12.9% B+ · D/E 0.54 B+ · P/E 18.1x B+ · PEG 0.88 B+
Why now. The bull case for CVSA rests on its ability to compound growth through its Chamberlain, Walden, and Medical and Veterinary segments, with a 12.9% revenue growth rate and a 18.1 P/E ratio that is reasonable for a growth name, especially considering its 0.88 PEG ratio, indicating the stock is fairly valued given its growth prospects. This growth persistence is key, as it allows CVSA to reinvest in its business and drive further expansion. The crux of this thesis is whether CVSA can maintain its revenue growth trajectory, particularly in its nursing and health professions programs.
Moat. CVSA's durable edge comes from its established position in the healthcare education market, particularly through its Chamberlain University and Walden University brands, which offer a range of degree and non-degree programs. The 17.2% ROE suggests that CVSA has pricing power, likely due to its category leadership in healthcare education, allowing it to maintain profitability even as it invests in growth initiatives. This advantage is difficult for competitors to replicate quickly, given the regulatory hurdles and investment required to establish similar programs.
Risk. The bear case against CVSA centers on its debt-to-equity ratio of 0.54, which, while not excessively high, indicates that the company has taken on some leverage. If CVSA's revenue growth were to slow significantly, its ability to service this debt could become a concern, potentially leading to a re-rating of the stock. A concrete signal that would confirm the bear case would be a decline in revenue growth below 5%, indicating that CVSA's growth trajectory is not as durable as anticipated.
Horizon. 1-3 yr $156.25 (analyst consensus (n=4)) — fundamentals + valuation re-rating. 5 yr $228.77 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $339.36 if current growth sustains into durable earnings power.
22. MELI — MercadoLibre, Inc. · score 81.9
Internet Retail · price $1619.25 · 1Y $2,217 · 5Y $3,246 · 10Y $4,815
1Y -35% D · Rev +34.3% A · ROE 26.4% A- · FCF $11.8b A-
Why now. The bull case for MELI rests on its ability to compound growth through Mercado Pago, its financial technology solution platform, which complements its e-commerce platform and drives 34.3% revenue growth. With a 42.8 P/E ratio and a 1.02 PEG ratio, the market is pricing in continued expansion, and the company's $11.8b in free cash flow supports investments in its ecosystem. The crux is whether Mercado Pago can sustain its growth trajectory, driving the stock towards its $2216.96 analyst consensus target.
Moat. MELI's durable edge stems from its Mercado Libre Marketplace and Mercado Pago, which create a network effect, increasing the value for both buyers and sellers as more users join the platform. The company's 26.4% ROE is a testament to its pricing power, driven by its category leadership in Latin America. This advantage is difficult for competitors to replicate quickly, as it requires significant investments in technology, logistics, and user acquisition.
Risk. The bear case against MELI centers on its high 1.7 debt-to-equity ratio and 1.35 beta, which may indicate increased volatility and sensitivity to market downturns. If the company's revenue growth decelerates or its profit margins contract, the stock's valuation multiples could compress, confirming the bear case. A concrete signal would be a decline in Mercado Pago's transaction volumes or a failure to expand its financial services offerings, which would undermine the bull thesis.
Horizon. 1-3 yr $2,217 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $3,246 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $4,815 if current growth sustains into durable earnings power.
23. PRDO — Perdoceo Education Corporation · score 81.4
Education & Training Services · price $32.98 · 1Y $37.93 · 5Y $55.53 · 10Y $82.37
FCF $225m C · Rev +24.2% A- · D/E 0.12 A- · P/E 12.6x A- · PEG 0.70 A-
Why now. The bull case for Perdoceo Education Corporation rests on its ability to compound growth through its career-oriented disciplines, particularly in the CTU segment, with a 24.2% revenue growth rate, a 12.6 P/E ratio, and a 0.7 PEG ratio, indicating the company's growth is undervalued. This growth is driven by the increasing demand for online and blended learning programs, and the company's strong profit margin of 19.9% suggests it can maintain its competitive edge. The crux of this thesis is that Perdoceo can continue to grow its revenue while maintaining its profitability, driven by its strong segments like CTU and AIUS.
Moat. Perdoceo's durable edge comes from its established position in the postsecondary education market, particularly in career-oriented disciplines like business and management, nursing, and computer science. The company's 17% ROE is a result of its pricing power, driven by its category leadership in these disciplines, which allows it to maintain its profit margins. Additionally, the company's low debt-to-equity ratio of 0.12 provides it with the financial flexibility to invest in its segments and maintain its competitive advantage.
Risk. The bear case for Perdoceo Education Corporation is that its growth may be hindered by increasing competition in the online education market, which could lead to a decline in its revenue growth rate. The company's 0.69 beta suggests that it is less volatile than the market, but its $2.1b market cap and 32.98 current price may make it vulnerable to market fluctuations. If the company's revenue growth rate were to decline, it could confirm the bear case and break the bull thesis, particularly if the decline is driven by a loss of market share in its key segments like CTU and AIUS.
Horizon. 1-3 yr $37.93 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $55.53 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $82.37 if current growth sustains into durable earnings power.
24. EPAC — Enerpac Tool Group Corp. · score 79.6
Specialty Industrial Machinery · price $37.07 · 1Y $42.63 · 5Y $62.42 · 10Y $92.59
FCF $111m C · Rev +4.6% C+ · D/E 0.46 B+ · P/E 23.3x B+ · PEG 0.34 A
Why now. The bull case for Enerpac Tool Group Corp. rests on its ability to compound growth through its highly engineered heavy lifting technology solutions, with a 23.3 P/E ratio indicating a reasonable valuation for its 4.6% revenue growth and 13.7% profit margin. This growth is driven by its presence in the infrastructure, industrial maintenance, and oil and gas markets, and is further supported by its 0.34 PEG ratio, suggesting the stock's price is justified by its growth prospects. The crux of this thesis is that Enerpac's growth will persist due to its strong position in these markets.
Moat. Enerpac's durable edge comes from its highly engineered heavy lifting technology solutions and branded hydraulic and mechanical tools, which provide a cost advantage and switching costs for its customers. The company's 21% ROE is a result of its pricing power from category leadership in these specialized tools, making it difficult for competitors to quickly replicate its offerings. Additionally, its global distribution network and presence in multiple markets provide a barrier to entry for new competitors.
Risk. The bear case against Enerpac Tool Group Corp. is centered around its debt-to-equity ratio of 0.46, which, although reasonable, could become a concern if interest rates rise or the company's cash flow decreases. Furthermore, the company's beta of 0.87 indicates a moderate level of market risk, and its reliance on a few key markets, such as infrastructure and oil and gas, makes it vulnerable to fluctuations in these industries. A concrete signal that would confirm the bear case is a decline in the company's profit margin or a significant increase in its debt levels.
Horizon. 1-3 yr $42.63 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $62.42 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $92.59 if current growth sustains into durable earnings power.
25. FIVE — Five Below, Inc. · score 79.2
Specialty Retail · price $186.59 · 1Y $261.57 · 5Y $382.97 · 10Y $568.11
FCF $505m C+ · Rev +22.9% A- · D/E 0.86 B · P/E 23.6x B · PEG 0.98 B+
Why now. The bull case for Five Below, Inc. rests on its ability to compound growth through its assortment of classic and novelty candy bars, movie-size box candy, and seasonal-related candy, with a 22.9% revenue growth rate, a 23.6 P/E ratio, and a 0.98 PEG ratio, all of which suggest the company's growth is reasonably priced. This growth is further supported by the company's $505m in free cash flow and 8.7% profit margin. The crux of this thesis is that Five Below can maintain its revenue growth rate while expanding its product offerings, including chilled drinks, socks, jewelry, and party goods.
Moat. Five Below's durable edge is its ability to offer a wide range of products at a low price point, creating a cost advantage that competitors can't quickly replicate. The company's 19% ROE is a result of its pricing power from category leadership in specialty value retail, particularly in its candy and snack food products. This advantage is further reinforced by the company's ability to sell personalized living space products, such as lamps, posters, and fleece blankets, which creates a loyal customer base.
Risk. The bear case against Five Below is that its debt-to-equity ratio of 0.86 and beta of 0.97 suggest the company may be vulnerable to economic downturns. Additionally, the company's reliance on a few key product categories, such as candy and snacks, creates a concentration risk. If the company's revenue growth rate were to slow, the bears would be right, and the stock price could decline. A concrete signal that would confirm the bear case is a decline in same-store sales or a decrease in the company's profit margin.
Horizon. 1-3 yr $261.57 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $382.97 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $568.11 if current growth sustains into durable earnings power.
26. WLDN — Willdan Group, Inc. · score 78.2
Engineering & Construction · price $78.93 · 1Y $90.77 · 5Y $132.90 · 10Y $197.14
FCF $43m C- · Rev +20.5% A- · D/E 0.22 A- · P/E 21.2x B+ · PEG 0.48 A
Why now. The bull case for WLDN rests on its ability to compound growth through its Energy segment, which offers comprehensive audit and surveys, program design and implementation, and software and data analytics, driven by a 20.5% revenue growth rate, a 21.2 P/E ratio, and a 0.48 PEG ratio, all of which suggest that the company's growth is both strong and reasonably valued, and it all hinges on the company's ability to maintain its 8.2% profit margin
Moat. WLDN's durable edge comes from its expertise in energy efficiency and grid optimization, which creates a high barrier to entry for competitors due to the complexity and nuance of these services, and its 18.2% ROE suggests that the company has significant pricing power, likely due to its category leadership in energy auditing and consulting, which allows it to maintain high margins and invest in further growth
Risk. The bear case against WLDN is that its 1.11 beta and 0.22 debt-to-equity ratio suggest that the company may be vulnerable to economic downturns and interest rate changes, and if the company's revenue growth were to slow, its 21.2 P/E ratio could become unsustainable, leading to a re-rating of the stock, and the key signal to watch for would be a decline in the company's 20.5% revenue growth rate
Horizon. 1-3 yr $90.77 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $132.90 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $197.14 if current growth sustains into durable earnings power.
27. DECK — Deckers Outdoor Corporation · score 78.1
Footwear & Accessories · price $102.59 · 1Y $126.86 · 5Y $185.73 · 10Y $275.52
FCF $1.1b C+ · Rev +9.8% B · D/E 0.15 A · P/E 14.6x A- · PEG 1.32 B
Why now. The bull case for DECK rests on the compounding growth of its HOKA brand, which is driving a 9.8% revenue growth rate, paired with a 18.7% profit margin and a 41% return on equity, indicating a high-quality earnings stream. This growth is further supported by the company's $1.1b in free cash flow, demonstrating its ability to generate cash and invest in its business. The crux of this thesis is that HOKA's strong brand positioning and product offerings will continue to drive growth, outpacing the broader footwear market.
Moat. DECK's durable competitive advantage stems from its portfolio of strong brands, including UGG, HOKA, and Teva, which have built significant customer loyalty and recognition. The company's 41% return on equity is a testament to its pricing power, driven by category leadership in the premium footwear segment. Additionally, the company's 0.15 debt-to-equity ratio provides a stable financial foundation, allowing it to invest in its brands and drive long-term growth.
Risk. The bear case for DECK centers on the potential for slowing growth in the footwear market, particularly if consumer spending patterns shift away from premium brands like HOKA and UGG. With a 14.6 P/E ratio and a 1.32 PEG ratio, the stock may be vulnerable to multiple compression if growth slows. A concrete signal that would confirm the bear case would be a decline in same-store sales or a miss on revenue growth, indicating that the company's premium brands are losing traction with consumers.
Horizon. 1-3 yr $126.86 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $185.73 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $275.52 if current growth sustains into durable earnings power.
28. HURN — Huron Consulting Group Inc. · score 78.1
Consulting Services · price $92.21 · 1Y $184.25 · 5Y $269.76 · 10Y $400.17
1Y -28% D · Rev +11.7% B · ROE 26.1% A- · FCF $124m C
Why now. The bull case for HURN rests on its ability to compound growth through its Healthcare, Education, and Commercial segments, driven by its digital services and financial and operational performance improvement consulting. With a revenue growth rate of 11.7%, a PEG ratio of 1.47, and a profit margin of 5.9%, HURN is poised for sustained expansion, and its current price of $92.21 offers a compelling entry point, given the analyst consensus 1-yr target of $184.25. The crux of this thesis is HURN's capacity to maintain its growth trajectory, underpinned by its diverse service offerings and segments.
Moat. HURN's durable edge stems from its expertise in digital services, including technology and analytic-related services, which creates a high barrier to entry for competitors due to the complexity and specificity of these services. The company's ROE of 26.1% is a testament to its pricing power, particularly in its Healthcare segment, where it has established strong relationships with clients, making it difficult for competitors to replicate its success quickly.
Risk. The bear case against HURN centers on its high debt-to-equity ratio of 2.24, which could pose a significant risk if interest rates rise or if the company faces a downturn in its operations. Additionally, with a beta of 0.09, HURN's stock may not be as volatile as the broader market, but its P/E TTM of 15.8 is not excessively low, suggesting that the market may already be pricing in some level of growth. A concrete signal that would confirm the bear case is a significant decline in revenue growth or a failure to meet analyst expectations, which could lead to a re-rating of the stock.
Horizon. 1-3 yr $184.25 (analyst consensus (n=4)) — fundamentals + valuation re-rating. 5 yr $269.76 at ~24% CAGR — compounding case rests on the competitive position widening. 10 yr $400.17 if current growth sustains into durable earnings power.
29. NFLX — Netflix, Inc. · score 78.1
Entertainment · price $70.90 · 1Y $114.15 · 5Y $167.12 · 10Y $247.91
1Y -45% D · Rev +15.9% B+ · ROE 43.0% A · FCF $11.9b A-
Why now. The bull case for NFLX rests on its ability to compound growth through its streaming content offerings, with a revenue growth rate of 15.9% and a profit margin of 28.5%, driven by its vast library of TV series, documentaries, feature films, and games. This growth is further supported by its free cash flow of $11.9B, which demonstrates the company's ability to generate cash and invest in its business. The crux of this thesis is that NFLX can maintain its high ROE of 43% through its pricing power and cost advantages, allowing it to continue compounding growth over time.
Moat. NFLX's durable edge is its ability to offer a wide range of streaming content across various genres and languages, which creates a network effect that makes it difficult for competitors to replicate. This is further supported by its high ROE of 43%, which is driven by its pricing power from being a category leader in streaming content. The company's ability to distribute its content through a host of internet-connected devices also creates a cost advantage that competitors cannot easily match.
Risk. The bear case for NFLX is that its high P/E ratio of 22.9 and debt-to-equity ratio of 0.54 make it vulnerable to a market downturn or a disruption in its streaming business. Additionally, the company's high beta of 1.49 indicates that it is more volatile than the overall market, which could lead to significant price swings. If NFLX's revenue growth rate were to slow down significantly, it could confirm the bear case and break the bull thesis.
Horizon. 1-3 yr $114.15 (analyst consensus (n=44)) — fundamentals + valuation re-rating. 5 yr $167.12 at ~19% CAGR — compounding case rests on the competitive position widening. 10 yr $247.91 if current growth sustains into durable earnings power.
30. DV — DoubleVerify Holdings, Inc. · score 77.7
Advertising Agencies · price $9.95 · 1Y $13.06 · 5Y $19.12 · 10Y $28.36
1Y -30% D · Rev +13.9% B+ · ROE 5.1% C+ · FCF $135m C
Why now. DoubleVerify's compounding growth rests on its ability to drive campaign performance through data-driven solutions like DV Authentic Attention and Custom Contextual, with a 13.9% revenue growth rate, $135m in free cash flow, and a 0.62 PEG ratio that suggests the growth is undervalued. The crux of this thesis is that DoubleVerify can sustain this growth by expanding its customer base and increasing adoption of its AI-powered digital campaign optimization solution, Scibids AI, which would further boost its 7.2% profit margin and 5.1% ROE.
Moat. DoubleVerify's durable edge comes from its comprehensive media effectiveness platforms, including DV Authentic Ad, which provides a metric of digital media quality, and Rockerbox, which enables advertisers to unify cross-channel conversion and spend data. This integrated suite creates a switching cost for customers, as they become reliant on DoubleVerify's data to drive campaign performance, making it difficult for competitors to replicate. The 0.09 debt-to-equity ratio also indicates a healthy balance sheet, allowing the company to invest in its products and further solidify its competitive position.
Risk. The bear case against DoubleVerify centers on the potential for decelerating growth, as evidenced by the 30.2 P/E ratio, which may be elevated given the 13.9% revenue growth rate. If DoubleVerify fails to expand its customer base or increase adoption of its solutions, its growth could slow, and the stock could correct. A concrete signal that would confirm this bear case is a decline in revenue growth below 10%, which would indicate that DoubleVerify is struggling to sustain its momentum.
Horizon. 1-3 yr $13.06 (analyst consensus (n=17)) — fundamentals + valuation re-rating. 5 yr $19.12 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $28.36 if current growth sustains into durable earnings power.
Methodology footnote
Every pick on this list comes out of the same quality-growth model — one 0–100 score blending quality, growth, and value — applied to every US-listed common stock with a market cap above $1B. Each pick's score breakdown is auditable from the home page — click the ticker on the rankings page to see exactly which grades produced the number. Not investment advice. See terms for full disclosures.